Lexeo Therapeutics, Inc. Common Stock
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Lexeo Therapeutics, Inc. is a clinical-stage genetic medicine company focused on developing innovative gene therapy treatments for hereditary and acquired cardiovascular diseases and APOE4-associated Alzheimer's disease. The company’s primary products include gene therapy candidates such as LX2006 for Friedreich’s ataxia (FA) cardiomyopathy; LX2020 targeting plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy; LX2021 for DSP cardiomyopathy; and LX2022 for hypertrophic cardiomyopathy caused by TNNI3 gene mutations. Lexeo develops these therapies using adeno-associated virus (AAV) based platforms and advanced genetic medicine technologies, aiming to address diseases with significant unmet medical needs. Headquartered in New York City and founded in the early 2020s, the company builds on pioneering research from institutions like Weill Cornell Medicine and the University of California San Diego and operates in the United States with a focus on global clinical development. Recent major developments include securing the U.S. FDA Breakthrough Therapy designation for LX2006, which accelerates its regulatory pathway for treating Friedreich’s ataxia cardiomyopathy; inclusion in the FDA's Chemistry, Manufacturing, and Controls Readiness Pilot program to streamline manufacturing processes; and significant progress in Phase I/II clinical trials demonstrating promising interim efficacy data. In mid-2025, Lexeo announced a strategic partnership with Perceptive Xontogeny Venture Funds and venBio Partners to develop non-viral RNA-based therapeutics for genetic cardiac diseases, supported by up to $40 million in private equity financing. This collaboration led to the creation of a new entity leveraging Lexeo’s expertise and preclinical intellectual property, with future milestone payments and royalties structured for Lexeo. Additionally, Lexeo closed an $80 million equity financing round to support its clinical pipeline, including ongoing advancements in LX2020 and other programs, and appointed new key leadership to strengthen its financial and operational capabilities. Lexeo’s innovative product pipeline targets cardiovascular and neurodegenerative disorders primarily in the genetic medicine and biotechnology industry segments. The company’s products are oriented toward patients suffering from rare genetic cardiac diseases and neurodegenerative conditions, with an emphasis on gene therapy and RNA-based therapeutic modalities. Lexeo Therapeutics continues to expand its pipeline and clinical development programs and engages with key stakeholders through scientific forums and virtual events to share progress and insights on managing genetic cardiac diseases. The company’s focus on precision genetic medicine and next-generation delivery platforms positions it at the forefront of transformative treatments for genetic diseases within the United States and globally.
Company News
Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM
Lexeo Therapeutics to Participate in the Chardan Healthcare Conference
Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson's Disease and Movement Disorders 2026 (MDS)
Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia
Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
Lexeo Therapeutics, Inc. (LXEO) M&A Call Transcript
Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia
BlackRock Inc. Takes Position in Lexeo Therapeutics, Inc. $LXEO
Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September
1,489,189 Shares in Lexeo Therapeutics, Inc. $LXEO Acquired by Avoro Capital Advisors LLC
Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights
Lexeo Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for LX2020 for the Treatment of PKP2 Arrhythmogenic Cardiomyopathy
Lexeo Therapeutics, Inc. (LXEO) Discusses Phase III Program Design and Durable Cardiac Improvements in Friedreich's Ataxia Transcript
Lexeo Therapeutics's LX2006 Has A Viable Regulatory Pathway And Timeline
Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia
Lexeo Therapeutics, Inc. (LXEO) Shareholder/Analyst Call Transcript
Why Is Lexeo Therapeutics Stock Gaining Monday?
Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia
Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights